

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 November 2022 (10.11.2022)



(10) International Publication Number
WO 2022/235786 A1

(51) International Patent Classification:

A61K 31/55 (2006.01) A61K 35/761 (2015.01)
A61K 38/18 (2006.01) A61P 27/02 (2006.01)
A61K 48/00 (2006.01)

(21) International Application Number:

PCT/US2022/027653

(22) International Filing Date:

04 May 2022 (04.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/185,897 07 May 2021 (07.05.2021) US

(71) Applicant: OYSTER POINT PHARMA, INC. [US/US];
202 Carnegie Center, Suite 109, Princeton, Washington
08540 (US).


(72) Inventors: NAU, Jeffrey Alan; c/o Oyster Point Pharma,
Inc., 202 Carnegie Center, Suite 109, Princeton, New Jersey
08540 (US). CARLSON, Eric C.; c/o Oyster Point Pharma,
Inc., 202 Carnegie Center, Suite 109, Princeton, New Jersey
08540 (US).

(74) Agent: MAYER, Mika R. et al.; Cooley LLP, 1299 Penn-
sylvania Avenue, NW, Suite 700, Washington, District of
Columbia 20004-2400 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

(54) Title: CO-THERAPY WITH VECTOR AND NICOTINIC AGONIST

FIG. 2



(57) Abstract: Methods that increase bioavailability and/or efficacy of a therapeutic agent for treatment of an ocular surface disorder, cornea disorder, or anterior chamber disorder are provided. In particular, tear production is increased by administration of an electrical stimulus, ultrasound stimulus, and/or a drug such as an nAChR $\alpha 7$ agonist (e.g., varenicline, (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, 5-((E)-2-((3R)-pyrrolidin-3-yl)vinyl)pyrimidine, or (R,E)-5-((2-pyrrolidine-3-yl)vinyl)pyrimidine). The primary therapeutic agents provided include recombinant adeno-associated virus (AAV) vectors expressing a therapeutic gene product (e.g., a biologic drug). Related compositions methods of use are also provided.

[Continued on next page]

WO 2022/235786 A1

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*